Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 15/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599711 | 0.83 | ALDH1A3 (0.44) | FFAR4ERN1ALDH1A3 | |
| SCHEMBL6928613 | 0.82 | ALDH1A3 (0.52) | FFAR4ERN1ALDH1A3 | |
| SCHEMBL14689988 | 0.82 | ALDH1A3 (0.42) | FFAR4ERN1ALDH1A3 | |
| SCHEMBL14690141 | 0.81 | FFAR4 (0.44) | FFAR4ERN1ALOX5APFEN1 | |
| SCHEMBL14285929 | 0.76 | ALDH1A3 (0.52) | FFAR4ERN1ALDH1A3 | |
| SCHEMBL1020456 | 0.75 | ALDH1A1 (0.47) | FFAR4ALDH1A3 | |
| SCHEMBL30829775 | 0.75 | ALDH1A1 (0.47) | FFAR4ALDH1A3 | |
| SCHEMBL24530453 | 0.73 | ALDH1A3 (0.57) | ERN1ALDH1A3 | |
| SCHEMBL16616210 | 0.71 | FFAR4 (0.43) | FFAR4ERN1AKR1C3AKR1C2ALOX5AP | |
| SCHEMBL6930848 | 0.71 | ALDH1A3 (0.53) | FFAR4ERN1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571356-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | FFAR4 122/4885ERN1 2810/4885AKR1C3 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.